Fuelling Immunity: How Cell Metabolism Influences Cancer Treatment Response
Posted on 2026-06-25
Cancer immunotherapies have undoubtedly transformed oncology, with durable responses being observed in cancers previously considered untreatable. Whilst some approaches remain under investigation, others are already firmly established in clinical settings. Yet, despite the positive outcomes observed, a proportion of patients have been shown to develop a resistance or simply fail to respond to the treatment at all. Understanding what may be causing these divergent outcomes, therefore remains a central challenge in cancer research.
Looking Beyond Genetics
Historically, research into immunotherapy resistance has focused largely on genetic influences, including checkpoint expression and tumour mutational burden (1). While genetic complexity remains an important focus, it provides only a partial explanation for the variability observed in clinical outcomes. Increasingly, attention has begun to shift towards the tumour microenvironment (TME), where metabolic constraints can shape immune cell function (2). Within this highly competitive landscape, immune cells are contending with limited nutrient availability, hypoxia, and a build-up of metabolic byproducts generated by tumour cells (3). Without sufficient energetic support, even activated immune cells may struggle to sustain an effective anti-tumour response.
What emerges within the TME is, in effect, a metabolic tug-of-war. Tumour cells rapidly adapt to fluctuating conditions to sustain their high energetic demands, often at the expense of infiltrating immune cells (2). One well-characterised example of this is the “Warburg effect”, whereby tumour cells preferentially utilise aerobic glycolysis despite adequate oxygen availability. Although this pathway generates less ATP per molecule of glucose compared with oxidative phosphorylation, it supports rapid metabolic flux and the generation of intermediates required to facilitate tumour proliferation (3). The resulting nutrient depletion and accumulation of metabolites such as lactate contribute to an immunosuppressive landscape, ultimately diminishing response to immunotherapy (4).
Mapping the Metabolic Landscape
Characterising the metabolic landscape of the TME is increasingly recognised as a key step toward better understanding, and potentially overcoming, immunotherapy resistance. Rather than being driven by a single pathway, resistance reflects a network of metabolic and immune interactions that influence cytokine signalling, effector function, and immune persistence. Capturing this complexity requires analytical approaches capable of assessing multiple immune mediators simultaneously, allowing researchers to identify signalling patterns that may correlate with therapeutic response.
Recent translational studies have begun to explore this approach in more detail. One example of this is the research undertaken by Monkman et al. (5). Their work looked to characterise the metabolic states of tumour and immune cells in patients with non-small cell lung carcinoma using multiplexed immunofluorescence (mIF) and computational modelling. Their findings illustrated that spatial and metabolic profiling of the TME can reveal features associated with response to immunotherapies, thus emphasising how integrated metabolic and immune analysis could uncover mechanisms of resistance and inform future therapeutic strategies.
The Future of Immunotherapy?
As understanding of tumour metabolism continues to expand, characterising the metabolic dynamics of the tumour microenvironment may offer new opportunities to improve immunotherapy outcomes. Metabolic biomarkers may help identify patients more likely to benefit from specific therapies, while integrated profiling of immune and metabolic pathways may reveal novel targets for combination treatments. Increasingly, tumour metabolism is not only being viewed as a driver of tumour progression, but also as a potential key to unlocking more effective immunotherapeutic strategies.
While immunotherapy has undoubtedly transformed the treatment landscape for many cancers, variability in patient response remains a major challenge. Growing evidence suggests that metabolic competition within the tumour microenvironment plays a critical role in shaping immune function and therapeutic outcomes. By integrating metabolic insight with comprehensive immune profiling, researchers are beginning to uncover the complex mechanisms underlying treatment resistance. Continued advances in technologies capable of capturing these interactions will be essential for improving our understanding of cancer biology and supporting the development of more effective immunotherapy strategies.
Finding the most specific and relevant tools is the cornerstone of effective research. At Abbexa we support cancer researchers worldwide by offering an extensive range of biological tools used to investigate immune responses and the tumour microenvironment.
Explore our range of cancer research essentials:
| ELISA kits | Antibodies | Protiens |
| Human Programmed Cell Death 1 Ligand 1 (CD274) ELISA Kit abx252917 | Programmed Cell Death Protein 1 (PDCD1) Antibody (PE) abx140362 | Human Interleukin 5 (IL5) Protein abx651531 |
| Human IL6/TNNI3/CCL2 Multiplex Assay Kit abx481022 | Forkhead Box Protein P3 (FOXP3) Antibody abx430531 | Human Versican (VCAN) Protein abx069660 |
| Human Interleukin-6 (IL6) ELISA Kit abx050124 | T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8A) Antibody (PE) abx140021 | 5'-Nucleotidase / CD73 (NT5E) Antibody (APC) abx140483 |
1. Havel, J. J., Chowell, D., & Chan, T. A. (2019). The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews. Cancer, 19(3), 133–150. https://doi.org/10.1038/s41568-019-0116-x
2. Zhang, H., Fan, J., Kong, D., Sun, Y., Zhang, Q., Xiang, R., Lu, S., Yang, W., Feng, L., & Zhang, H. (2025). Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy. Molecular Cancer, 24(1), 249. https://doi.org/10.1186/s12943-025-02460-1
3. Cabezón-Gutiérrez, L., Palka-Kotlowska, M., Custodio-Cabello, S., Chacón-Ovejero, B., & Pacheco-Barcia, V. (2025). Metabolic mechanisms of immunotherapy resistance. Exploration of Targeted Anti-Tumor Therapy, 6, 1002297. https://doi.org/10.37349/etat.2025.1002297
4. Shende, S., Rathored, J., & Budhbaware, T. (2025). Role of metabolic transformation in cancer immunotherapy resistance: molecular mechanisms and therapeutic implications. Discover Oncology, 16(1), 453. https://doi.org/10.1007/s12672-025-02238-3
5. Monkman, J., Kilgallon, A., Lawler, C., Tubelleza, R., Aung, T. N., Warrell, J. H., Vathiotis, I., Trontzas, I. P., Gavrielatou, N., Nyein Chan, N. N., Czertok, R., Bookstein, S., O'Byrne, K., Markovits, E., Rimm, D. L., & Kulasinghe, A. (2026). Metabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC). Nature Communications, 17(1), 837. https://doi.org/10.1038/s41467-026-68633-8
